Ivor Royston M.D.
Net Worth

Last updated:

What is Ivor Royston M.D. net worth?

The estimated net worth of Dr. Ivor Royston M.D. is at least $2,085,861 as of 25 Nov 2024. He owns shares worth $5,993 as insider, has earned $252,868 from insider trading and has received compensation worth at least $1,827,000 in Viracta Therapeutics, Inc..

What is the salary of Ivor Royston M.D.?

Dr. Ivor Royston M.D. salary is $456,750 per year as Chief Executive Officer, Pres & Director in Viracta Therapeutics, Inc..

How old is Ivor Royston M.D.?

Dr. Ivor Royston M.D. is 79 years old, born in 1946.

What stocks does Ivor Royston M.D. currently own?

As insider, Dr. Ivor Royston M.D. owns shares in one company:

Company Title Shares Price per share Total value
Viracta Therapeutics, Inc. (VIRX) Chief Executive Officer, Pres & Director 612,770 $0.01 $5,993

What does Viracta Therapeutics, Inc. do?

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

VIRX logo
VIRX
Viracta Therapeutics, Inc.
$0.01

Ivor Royston M.D. insider trading

Viracta Therapeutics, Inc.

Dr. Ivor Royston M.D. has made 5 insider trades between 2021-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 50,437 units of VIRX stock on 25 Nov 2021. As of 25 Nov 2024 he still owns at least 612,770 units of VIRX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Common Stock 25,219 N/A N/A
Sale
Common Stock 13,379 $4.01 $53,663
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Sale
Common Stock 13,162 $1.9 $25,021
Option
Common Stock 25,219 N/A N/A
Option
Restricted Stock Units 25,219 N/A N/A
Sale
Common Stock 14,635 $2.78 $40,685
Option
Common Stock 25,219 N/A N/A
Option
Common Stock 7,000 $0.9 $6,300
Option
Stock Option (Right to Buy) 7,000 $0.9 $6,300
Option
Restricted Stock Units 50,437 N/A N/A
Sale
Common Stock 15,833 $4.82 $76,299
Sale
Common Stock 11,914 $4.8 $57,199
Option
Common Stock 50,437 N/A N/A
Purchase
Common Stock 8,000 $5.56 $44,480

Viracta Therapeutics key executives

Viracta Therapeutics, Inc. executives and other stock owners filed with the SEC: